https://doi.org/10.48047/AFJBS.6.13.2024.7193-7201

African Journal of Biological Sciences

Journal homepage: http://www.afjbs.com

Research Paper Open Access

UNDERSTANDING CANCER COMPLEXITY THROUGH CELL LINE MODELS: CURRENT INSIGHTS AND FUTURE DIRECTIONS

Shreya Talreja[1] & Prof. Dr. Shashank Tiwari[2]

1Research Scholar Faculty of Pharmacy, Bhagwant University, Ajmer, Rajsthan, India

2 Research Supervisor Faculty of Pharmacy, Bhagwant University, Ajmer, Rajsthan, India

Volume 6, Issue 13, Aug 2024

Received: 15 June 2024

Accepted: 25 July 2024

Published: 15 Aug 2024

doi: 10.48047/AFJBS.6.13.2024.7193-7201

Abstract:

The use of cell lines is crucial for cancer-related research and provides a stripped-down version of the disease that can be used to study tumour biology, drug response, and therapeutic strategies. This abstract gives an overview of some known cancer cell lines through which their origins, characteristics, applications and limitations will be discussed. We specifically look at breast (MCF-7, MDA-MB-231), colorectal (HCT-116, SW620), prostate (LNCaP, PC-3), and lung (A549, H1975) cancers. Each line has unique characteristics that make it important when studying different elements of malignant growths' progression mechanisms towards drug resistance as well as intervention methods applied. However, the challenges such as genetic drift and phenotypic variations from primary tumours call for cautious interpretation of findings. In future models such as patient derived organoid cultures or xenografts should therefore be integrated in order to bring about better clinical relevance in line studies hence increasing the speed toward personalized treatment strategies for cancer patients. This review summarizes current information while proposing avenues for further exploration on how best to deploy cancer cell lines in tackling most pressing oncological questions.

Keywords:

Cancer cell lines, breast cancer, colorectal cancer, prostate cancer, lung cancer, MCF-7, MDA-MB-231, HCT-116, SW620, LNCaP, PC-3, A549, H1975, tumour biology, drug response, therapeutic strategies, genetic drift, translational research, personalized medicine

Introduction:

Global health is still grappling with cancer, a menace that comes in many forms genetically and clinically complicating the treatment plans. Amid this intricate situation, cancer cell lines have been found useful for research because they provide an easy mode to investigate some characteristics of normal cells as well as tumour biology within controlled environment.

Such cell line models can be used to test important biological processes such as proliferation, apoptosis, invasion and drug resistance due to their origin from primary human tumours. These cell lines maintain major phenotypic and genotypic features of the parental tissue and hence are valuable tools for investigating the basis of carcinogenesis and screening therapeutic agents.

This introduction reviews some notable cancer cell lines studied across different kinds of cancer alongside their sources, traits and primary uses in medical research. It is our goal through examining these models to underscore their significant roles in deciphering cancer biology as well as devising novel therapeutic strategies.

In addition, cell lines from cancer have many potential advantages such as being highly reproducible and scalable but also with disadvantages: genetic drift due to continuous use over time and well known differences compared primary tumors. These results support the idea data must be cautiously interpreted, and underline an urgent requirement for improved models which more closely recapitulate human cancers (such as patient-derived xenografts [PDGs] and organoids) to prevent disparities like these.

In general, cancer cells act as a link between fundamental research findings and medical applications in oncology. Through reviewing how these findings aid in understanding cancer in recent times, this paper intends to give an inclusive overview of their importance plus possibilities for future advances in personalized therapy for cancer treatment.

We will proceed to particular cases concerning some well-known cancer cell lines as well as tackle on their peculiarities, applications, restrictions and future developments within the field of cancer study.



Chart of Various Cell Lines

Breast Cancer Cell Lines:

Breast cancer is a very diverse condition, having heterogeneous diseases that consist of different molecular subtypes, each with distinct biological behaviours and also treatment responses. A number of widely accepted breast cancer cell lines are important in understanding the complexities of this disease and developing new therapeutic strategies. This paper examines two well-known breast cancer cell lines: MCF-7 and MDA-MB-231.

1. MCF-7:

Description: Established in 1970 for study on the estrogen receptor; derived from pleural effusion of a metastatic breast cancer patient. First of all, they are estrogenic receptor (ER)-

positive and progesterone receptor (PR)-positive; this makes them representative for hormone-dependent breast cancers.

Applications: MCF-7 cells are used extensively to investigate hormone receptor signalling pathways, endocrine resistance mechanisms and the effects of estrogenic and anti-estrogenic therapies. These technologies formed the basis of treatments such as tamoxifen and aromatase inhibitors.

The second limitation is similar to Cosh et al. and refers more directly to the topology of MCF-7 cells: even though widely studied, they are not enough for full depiction of all breast cancer subtypes or less hormone receptor-positive/types with some features we relate to aggressive forms (ERBB2-enriched or basal-like).

2. MDA-MB-231:

Line: MDA-MB-231 cells were obtained from a pleural effusion of a patient diagnosed with metastatic mammary adenocarcinoma and are renowned for their highly invasive phenotype references. These are triple-negative breast cancer (TNBC) cells, as they do not express the ER, PR and HER2 receptors.

Applications: MDA-MB-231 cells are used as a model for aggressive breast cancer biology, such as metastasis and invasion mechanisms or drug resistance. They represent a TNBC model, which is an aggressive subtype of breast cancer with limited treatment options and associated with inferior survival outcomes.

Drawback : Although widely used to model TNBC, MDA-MB-231 may not be a fully faithful representation of the heterogeneity found in this subtype. Given the study methods, clinicians should be cautious when generalizing to other clinical contexts.

Future Directions:
Research is evolving such that, there is progressively more focus on improving the translational capacity of breast cell line models to incorporate heterogeneity present in patient tumours. This entails expanding available cell line panels to be more representative of molecular subtypes, and using 3D culture systems, organoids and xenografts in patient derived formats. These approaches offer the potential to refine individualized treatment plans and maximize breast cancer outcomes.
Consequently, breast cancer cell lines can contribute with MCF-7 and/or MDA-MB-231 cells in the study of morphological, genetic base station activity and for testing some aspects of therapeutic development. Continued use in parallel with advances systems underscores the central position they hold as model animals within translational research endeavours to ameliorate this multifactorial disease.

Colorectal Cancer Cell Lines:

Colorectal cancer (CRC) is a major contributor to global burden of disease, associated with the molecular heterogeneity and prognosis outcome. Cell lines from CRC tumours have greatly contributed to knowledge of the disease process and for testing new therapeutic types. We chose to investigate two CRC Cell lines that are well characterized: HCT-116 and SW620.

1. HCT-116:

Derived from metastatic site; Cells were described to spend twelve days in a G starting cell cycle after being split. They show features of MSS CRC and have been used in research extensively because of their defined genome and stable karyotype.

Applications: HCT-116 cells are used to examine molecular pathways which play a role in the progression of colorectal cancer (CRC), disease treatment, and gene targeting applications. They have been instrumental in the identification of cardinal mutations, such as those in APC that are frequent events in CRC.

Limitations: All cell lines, including HCT-116 cells have limitations such as genetic drift over time and differences from primary tumours reflecting the heterogeneity seen in patient samples. This may necessitate validation of findings using more complex models or with patient material.

2. SW620:
Identity and Characteristics: SW620 is a derivative cell line of SW480, which in turn originates from a metastatic site (mesenteric lymph node) within the same patient from whom SW480 was established. The SW620 cells are more aggressive than the parent SW480 line.

Applications: SW620 cells are of particular interest as it is one of the best models available for colorectal cancer metastasis and studying mechanisms by which CRC resistance to drugs, more in advanced stages. Differentially expressed genes during CRC progression, giving information about molecular changes at different stages of the disease.

Restrictions: The limitations of using any cell line is that it does not behave like in vivo primary tumours due to lack heterogeneous and microenvironment factors.

Future Directions:
Future progress in areas such as CRC research will undoubtedly see more improved versions of the existing cell line models to encompass a wider array of properties shared by an even broader range and greater diversity of CTC subtypes, while also incorporating novel model systems like patient-derived organoids or xenografts. The integration of these technologies may enhance the translational utility in normalizing cell line-based studies, thereby facilitates rationalized personalized cancer treatment for CRC patients.

In conclusion, CRC cell lines as HCT-116 and SW620 play a central role in unravelling the serrate lineaments of colorectal cancer at molecular level to all intents and purposes promoting new therapeutical intuitions. This solid lineage and integration of them in emerging model systems may herald further advances to be made against this disease.

Prostate Cancer Cell Lines:
Prostate cancer is a major health problem worldwide and serves as an example for the presence of multiple molecular subtypes with different clinical behaviour. Prostate tumor-derived cell lines have been indispensable in our understanding of disease progression, mechanisms of therapeutic resistance and for the development and testing novel treatment approaches. We make use of two well-known prostate cancer cell lines: LNCaP and PC-3.

1. LNCaP:
Source: LNCaP cells were established from the lymph node of a human prostate adenocarcinoma. The hormone responsive LNCaP cells, an androgen-sensitive human prostate

cancer cell line express functional AR and comprise a good model for the study of different signalling pathways in hormonal regulation of prostatic growth.

Applications: LNCaP cells have also been extensively used to study androgen receptor signalling, mechanisms of resistance to anti-androgens in the clinic as well as screen antimedicandro-genesis therapies. They are essential tools to investigate the biology of early stage prostate cancer and its response to hormonal therapies.

Drawbacks: LNCaP cells, while providing insight into prostate cancer progression through AR signalling and regulation of the proliferation rate (and is therefore medically important), may not recapitulate how other aspects of prostate-such as aggressive forms that become treated with an anti-androgen treatment. These limitations should be considered by researchers interpreting the VP results.

2. PC-3:

Parent and Category: PC-3 cells, human prostate adenocarcinoma cell from a bone metastasis. They are AR-independent (AR-negative) and display characteristics of high grade cancer.

Applications: PC-3 cells are popular for studying prostate carcinoma biology, especially in the context of metastasis, tumour progression and resistance to therapeutics. In addition to ALK, one of these was Cdk12. They are known targets for castration-resistant prostate cancer (CRPC), often associated with a poor prognosis and limited response to treatment.
Drawbacks: Much like LNCaP, PC-3 cells have some shortcomings in modelling the complete spectrum of prostate cancer heterogeneity and crosstalk with the tumour microenvironment.

Future Directions:
In the near future, next-generation research on prostate cancer cell line studies include expanding source diversity to molecular subtypes and treatment-resistant phenotypes. Developments in utilizing advanced model systems including PDX and organoids provide optimism to mimic clinical settings more efficiently for the purpose of enhancing personalized therapeutic strategies.

Finally, prostate cancer cell lines including LNCaP and PC-3 have been invaluable for studying various aspects of biology in the realm of this disease as well as facilitating drug discovery efforts. Ongoing use, coupled with the evolution of model systems to address cancer phenotypes in patients have demonstrated their essential value for translational research focused on better treatment strategies for prostate-cancer patients.

Lung Cancer Cell Lines:

Lung cancer is the leading cause of cancer-related mortality in an increasingly wide area worldwide, and non-small cell lung (NSCLC)clinical practice has to adapt histological and molecular features as well their diverse subtypes that can rise individual challenges into diagnosis treatment or management. Cell lines derived from human lung cancer (CLH) tumours are invaluable tools for studying disease aetiology, identification of therapeutic targets and testing novel treatment strategies. In this study, we investigated two popular lung cancer cell lines: A549 and H1975.

1. A549:

Source and Development: A549 is a human lung carcinoma cell that was obtained from 58 years old male patient with both type II pneumocytes which forms the primary tissue components of alveoli epidermal properties. These are adenocarcinoma cells that represent a good model for non-small cell lung cancer (NSCLC).

Applications: A549 cell line was used in lung cancer biology, epidermal growth factor receptor expression profile and drug sensitivity testing, E-cadherin regulation research of epithelial cells. These screens are useful for and predicting effective anticancer drug candidates as well as the signalling pathways that operate in lung cancer progression.

Drawback: A549 is only a few examples, and they do not accurately capture the heterogeneity of full lung cancer spectrum especially other subtypes (e.g., small cell lung cancer SCLC). Researchers need to take into account of these constraints in the interpretation of experimental results.

2. H1975:
H1975 (Female)Was established from lung adenocarcinoma HGF transformed epithelial cells, 59 years old in vivo and developed resistance to gefitinib chemotherapy; expressed proteins were all wild-type or WT. This is a model for the canonical T790M mutation in EGFR and acquired resistance of lung cancer.

Applications: H1975 cells are ideal for investigating mechanisms of resistance to EGFR-targeted therapies that frequently occur in the treatment of EGFR-mutant NSCLC. They shed light on the molecular alterations in acquired resistance and help advance next-generation inhibitors.

Weaknesses: H1975 cells (hardly like A549) only represent one of several subpopulations in lung cancer with select genetic mutations. We need other models because different types of lung cancer and therapeutic response are represented.

Future Directions:
The logical progression of lung cancer cell line research for the future includes increasing numbers and types of models appropriate to diverse histologist and resistance mechanisms. The use of more sophisticated model systems (eg: patient-derived xenografts, organoids and cell co-culture with immune cells) is expected to better recapitulate the tumour microenvironment providing higher translational potential for findings obtained in preclinical studies.

Consequently, the lung cancer cell lines including A549 and NCI-H1975 have emerged as critical tools for studying pathogenesis of lung cancers as well as discovery of target therapies. Their continued use in conjunction with emergent-modelling platforms is necessary to advance personalized treatment approaches and optimize outcomes for patients with lung cancer.
Problems and Considerations in the Use of Cancer Cell Lines

Cell lines derived from cancers are valuable tools for the study tumour biology, drug responsiveness and therapeutic approaches in research. Nevertheless, those advantages bring with them a variety of challenges which researchers need to take care so that the data they collect is reliable and you know - useful.

1. Genetic and Phenotypic Drift:

Problem: That cancer cell lines in culture can accumulate intra- and inter-line genetic/phenotypic heterogeneity over-time, deviating towards alternative cellular malignant transformation of the originating tumour.

Critical: Performing periodic authentication of cell lines (eg, using short tandem repeat [STR] profiling) and services delivering phenotypic traits to ensure proper identification is the only way to truly maintain data consistency.

2. Tumours as representatives of a heterogenous system:

Problem: Cancer cell lines may be a reduced version of tumours and not present the same varieties seen in patient samples.
Some researchers may argue that more complex models (i.e. patient derived xenograft, organoids or primary tumour samples) are time- and resource-consuming compared to cell line studies, but they provide validation of findings in a system most likely representing pre-clinical situation.

3. **Culture Condition And Neighbourhood**

Problem: Cell lines are generally grown in vitro which is not representative of the intricate tumour micro-environment, i.e. interactions with immune cells and stroma cell components or extracellular multiciliary constituents.

Suggestion: To this end, the validity of experimental results should be enhanced by employing co-culture systems instead of single cell monocultures in combination with 3D cultures or organoid models simulating a more natural and complex tumour microenvironment.

4. Drug Sensitivity and Resistance

Problem: The cancer cell lines are likely to behave differently from the patient tumours just by virtue of being an independent genetic background and adapting into 2D in vitro setting.
Possible points: A broad use of cell lines and susceptibility in patient-derived models can increase the possibility that robust drug responses or resistance mechanisms demonstrated using one approach will indeed be translatable into clinical settings.

5. Important Ethical and Regulatory Considerations:
Concerns: Human-derived cell lines have ethical issues such as obtaining consent for establishment and compliance with human subject research's ethics.
Conception: Researchers are required to comply with ethical standards, obtain relevant approvals for the cell-line use and report methodologies and data in a transparent manner.

6. Standardization and Interpretation of Data

Problem: The heterogeneity of experiments and interpretation between laboratories undermined reproducibility and reliability.
Discussion: Developing guidelines, offering data or cell line repositories for sharing information and working together with other research groups could increase reproducibility as well as validation of critical new insights.

7. Alternative Model Systems:

Problematic: Cell lines are informative but do not necessarily recapitulate the heterogeneity of human tumours.
Integration of complementary model systems including patient-derived xenografts, organoids and ex vivo cultures are discussed to extend our understanding on tumour biology as well as for therapeutic response.

Understanding these challenges and considerations is essential to exploit the potential usefulness of cancer cell lines in studies investigating many facets of cancer biology as well as tumour-targeting experiments. Utilizing multiple model systems and rigorous experimental standards will increase the translational relevance of our research, hopefully leading to more efficacious treatments for cancer patients.

Conclusion

Cancer cell lines have transformed cancer research, offering vital platforms for dissecting tumour biology and for testing therapeutic opportunities as well as personalised medicine. In the years that followed, these cell lines played a critical role in unravelling many of the mechanisms underlying cancer initiation and progression as well as identifying drug responses or resistance mechanisms across multiple cancer types.

But challenges and opportunities await us as we pivot to the future. Improving the representativeness of cancer cell lines to achieve higher-fidelity approximations of human tumour complexity and heterogeneity is still a long-sought minimum goal. Incorporating these more advanced model systems such as patient-derived xenografts and organoids, holds potential to create a better linkage between lab research and clinical studies giving birth to biological models that are closer predictors of responses for drug discovery or personalized treatment strategies.

Additionally, progress will be made in genomic technologies for cancer where CRISPR/Cas9 based genetic manipulation and multi-omics profiling are likely to allow us insight into the molecular mechanism underlying oncogenesis. These efforts will identify additional therapeutic targets, biomarkers and mechanisms of drug resistance to further drive innovation in cancer treatment.

Standardization of experimental protocols, validation strategies and ethical concerns in terms of the use of human-derived cell lines are necessary to ensure reliability and reproducibility. Sharing open data and collaborating between researchers will help to bring even more discoveries forward, as well as improving the speed of translating research insights into real-world benefits for cancer patients.

In summary, the cell lines available to us provide an undeniable framework for radical insight and therapeutic progress. With the help of advancing technology and resolving the current bottlenecks, it will take a step ahead towards enhancing cancer cure which would cater to personalized care for Cancer. Ongoing investment in cancer cell line research will be critical to this and so we can properly see tangible improvements in patient outcomes across the globe.

Source of Funding- Self Funded

Conflict of Interest- Nil

Acknowledgements: The author extends heartfelt gratitude to all mentors for their invaluable guidance. The papers compiled here have been collected over an extended period and may have been reproduced verbatim. The author apologizes to any researchers who may have been inadvertently omitted from the references.

References

1. Gazdar, Adi F., and John D. Minna. "Diverse molecular targets for therapy of lung cancer." Lung Cancer, vol. 34, no. Suppl 2, 2001, pp. S21-S27. DOI: [10.1016/s0169-5002(01)00285-6](https://doi.org/10.1016/s0169-5002(01)00285-6).

2. Masters, John R. "HeLa cells 50 years on: The good, the bad and the ugly." Nature Reviews Cancer, vol. 2, no. 4, 2002, pp. 315-319. DOI: [10.1038/nrc775](https://doi.org/10.1038/nrc775).

3. Dangles-Marie, Virginie, et al. "Cancer cell lines: not only tools for the study of cancer." Biology of the Cell, vol. 92, no. 3, 2000, pp. 99-110. DOI: [10.1016/s0248-4900(00)01062-2](https://doi.org/10.1016/s0248-4900(00)01062-2).

4. Shoemaker, Robert H. "The NCI60 human tumour cell line anticancer drug screen." Nature Reviews Cancer, vol. 6, no. 10, 2006, pp. 813-823. DOI: [10.1038/nrc1951](https://doi.org/10.1038/nrc1951).

5. Gillet, Jean-Pierre, et al. "Clinical relevance of multidrug resistance gene expression in ovarian serous carcinoma effusions." Molecular Pharmacology, vol. 74, no. 3, 2008, pp. 843-852. DOI: [10.1124/mol.108.048975](https://doi.org/10.1124/mol.108.048975).

6. Barretina, Jordi, et al. "The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity." Nature, vol. 483, no. 7391, 2012, pp. 603-607. DOI: [10.1038/nature11003](https://doi.org/10.1038/nature11003).

7. Neve, Rachel M., et al. "A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes." Cancer Cell, vol. 10, no. 6, 2006, pp. 515-527. DOI: [10.1016/j.ccr.2006.10.008](https://doi.org/10.1016/j.ccr.2006.10.008).

8. Reya, Tannishtha, et al. "Stem cells, cancer, and cancer stem cells." Nature, vol. 414, no. 6859, 2001, pp. 105-111. DOI: [10.1038/35102167](https://doi.org/10.1038/35102167).

9. Horowitz, Neil S., et al. "Validation of the Oncotype DX Recurrence Score in a contemporary cohort of patients with hormone receptor-positive, HER2-negative, node-negative breast cancer." The Oncologist, vol. 24, no. 10, 2019, pp. 1379-1388. DOI: [10.1634/theoncologist.2019-0254](https://doi.org/10.1634/theoncologist.2019-0254).

10. Weiss, Frederick U., et al. "Molecular genetic features of colorectal cancer." World Journal of Gastroenterology, vol. 15, no. 46, 2009, pp. 5561-5571. DOI: [10.3748/wjg.15.5561](https://doi.org/10.3748/wjg.15.5561)